The DYNLT1 Knockout 786-O Polyclonal Cells provide a CRISPR/Cas9-edited polyclonal knockout cell population in which the human DYNLT1 gene has been disrupted. This product consists of a heterogeneous pool of 786-O cells carrying diverse loss-of-function mutations, offering a robust tool for investigating dynein light chain function without clonal expansion. The polyclonal format captures the spectrum of CRISPR-induced modifications, making it well-suited for functional genomic screens and phenotypic analyses in a cancer model system.
The 786-O cell line originates from a human renal cell adenocarcinoma and serves as a canonical model for clear cell renal cell carcinoma (ccRCC). These epithelial cells harbor characteristic VHL mutations and maintain molecular features of ccRCC, including dysregulated hypoxia and metabolic pathways. The 786-O background thus provides a clinically relevant platform for studying how dynein-dependent processes influence tumor phenotypes such as proliferation, migration, and primary cilium signaling.
DYNLT1 encodes a light chain subunit of cytoplasmic dynein, a motor complex driving minus-end-directed transport along microtubules. It directly interacts with dynein heavy chain (DYNC1H1) and intermediate chain (DYNC1I1), associates with the dynactin complex, and engages cargo adaptors like BICD2. Phosphorylation by CDK1 regulates DYNLT1 during mitosis, and its downstream roles include mitotic spindle assembly, retrograde trafficking of vesicles and organelles, and ciliary protein transport. Through these functions, DYNLT1 intersects with the Wnt signaling pathway, linking dynein activity to cell fate and development.
Disruption of DYNLT1 in 786-O cells may compromise dynein-mediated retrograde transport and spindle organization, potentially leading to mitotic defects, altered ciliary signaling, and impaired intracellular trafficking. Because primary cilia are crucial for Wnt pathway modulation and are often dysregulated in cancer, this polyclonal knockout model enables exploration of the mechanistic links between dynein dysfunction and ccRCC pathogenesis. The heterogeneity of mutations in the population mirrors the genetic diversity seen in tumor environments, enhancing the translational relevance of findings.
Researchers can employ these cells in a variety of assays, including western blotting and immunofluorescence to assess dynein complex localization, cell cycle analysis to examine mitotic progression, cilia formation assays to evaluate ciliary signaling, and migration or invasion studies to probe metastatic behavior. Proliferation assays further enable measurement of growth changes upon DYNLT1 loss. This polyclonal knockout model thus supports drug discovery and fundamental studies of dynein-related pathologies. For additional details, contact Ascent Research.
